FDA Clearance Tracker · P890047-S048
PROVISC Ophthalmic Viscosurgical Device (latex-ftee packaging configuration)
Last checked: Nov 20, 2026Latest source record: Oct 31, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Oct 31, 2017
Approved
Time to decision
467 days
Received Jul 21, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P890047-S048
- Device name
- PROVISC Ophthalmic Viscosurgical Device (latex-ftee packaging configuration)
- Applicant
- Alcon Research, Ltd.
- Applicant location
- Fort Worth, TX
- Received
- Jul 21, 2016
- Decided
- Oct 31, 2017
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P890047
Device type
- Device type
- AID, SURGICAL, VISCOELASTIC (LZP)
- Device class
- Class III
- Regulation
- 21 CFR 886.4275
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for a manufacturing site change located at Lifecore Biomedical, LLC., 3515 Lyman Boulevard, Chaska, Minnesota, USA, and Lifecore Biomedical, LLC, 1245 Lakeview Drive, Chaska, Minnesota, USA.
Source documents
Other decisions for Alcon Research, Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- AcrySof IQ PanOptix Trifocal Intraocular Lens and AcrySof IQ PanOptix Toric Trifocal Intraocular LensPMA supplement
P040020-S087 · Decided Aug 26, 2019 · 207 days after receipt · Panel Track
Device type: Lens, multifocal intraocular (MFK) · Ophthalmology
K161794 · Decided Apr 14, 2017 · 288 days after receipt
Device type: Unit, Phacofragmentation (HQC) · Ophthalmology
- HyperVit Vitrectomy Probe, 23 GA, HyperVit Vitrectomy Probe, 25+, HyperVit Vitrectomy Probe, 27+510(k)
K170520 · Decided Mar 22, 2017 · 28 days after receipt
Device type: Vitrectomy, Instrument Cutter (MLZ) · Ophthalmology
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.